MedTrace Logo

Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder

NCT00706589 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2013-07-26

Study results available
· View outcomes & findings →

Summary

The purpose of this trial is to demonstrate the efficacy and safety of aripiprazole in children and adolescents aged 6\~18 years with chronic tic disorders or Tourette's disorder

Conditions

  • Chronic Motor or Vocal Tic Disorder
  • Tourette's Disorder

Interventions

DRUG

aripiprazole

Initial dose : 2mg, Maximum dose : 20mg

DRUG

placebo

Initial dose: 2mg, Maximum dose:20mg

Sponsors & Collaborators

  • Otsuka Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Korea Otsuka Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Soochurl Cho, MD. Ph.D · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00706589 on ClinicalTrials.gov